Literature DB >> 14742225

Plasma pharmacokinetics of sulfadiazine administered twice daily versus four times daily are similar in human immunodeficiency virus-infected patients.

M Kelli Jordan1, Aaron H Burstein, Diane Rock-Kress, Raul M Alfaro, Alice K Pau, Joseph A Kovacs, Stephen C Piscitelli.   

Abstract

The pharmacokinetics of 2,000 mg of sulfadiazine administered twice daily (BID) versus those of 1,000 mg administered four times a day were compared in eight human immunodeficiency virus-infected patients. No differences in pharmacokinetic parameters were detected between the regimens. These data provide a pharmacokinetic rationale for BID dosing of sulfadiazine for the treatment and suppression of toxoplasmosis.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 14742225      PMCID： PMC321534          DOI： 10.1128/AAC.48.2.635-637.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  12 in total

Review 1.  Sulfadiazine-associated nephrotoxicity in patients with the acquired immunodeficiency syndrome.

Authors:  K Becker; H Jablonowski; D Häussinger
Journal:  Medicine (Baltimore)       Date:  1996-07       Impact factor: 1.889

2.  Thrice-weekly sulfadiazine-pyrimethamine for maintenance therapy of toxoplasmic encephalitis in HIV-infected patients. Spanish Toxoplasmosis Study Group.

Authors:  D Podzamczer; J M Miró; E Ferrer; J M Gatell; J M Ramón; E Ribera; G Sirera; A Cruceta; H Knobel; P Domingo; R Polo; M Leyes; J Cosin; M C Fariñas; J Arrizabalaga; J Martínez-Lacasa; F Gudiol
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2000-02       Impact factor: 3.267

3.  Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations.

Authors:  K Yamaoka; T Nakagawa; T Uno
Journal:  J Pharmacokinet Biopharm       Date:  1978-04

4.  Central nervous system toxoplasmosis in AIDS patients: efficacy of an intermittent maintenance therapy.

Authors:  E Pedrol; J M González-Clemente; J M Gatell; J Mallolas; J M Miró; F Graus; R Alvarez; J M Mercader; J Berenguer; M T Jiménez de Anta
Journal:  AIDS       Date:  1990-06       Impact factor: 4.177

Review 5.  Saquinavir soft-gel capsule formulation. A review of its use in patients with HIV infection.

Authors:  C M Perry; S Noble
Journal:  Drugs       Date:  1998-03       Impact factor: 9.546

6.  Twice-weekly maintenance therapy with sulfadiazine-pyrimethamine to prevent recurrent toxoplasmic encephalitis in patients with AIDS. Spanish Toxoplasmosis Study Group.

Authors:  D Podzamczer; J M Miró; F Bolao; J M Gatell; J Cosín; G Sirera; P Domingo; F Laguna; J Santamaría; J Verdejo
Journal:  Ann Intern Med       Date:  1995-08-01       Impact factor: 25.391

Review 7.  Clinical pharmacokinetics of co-trimazine.

Authors:  T Bergan; B Ortengren; D Westerlund
Journal:  Clin Pharmacokinet       Date:  1986 Sep-Oct       Impact factor: 6.447

8.  Adverse cutaneous reactions to pyrimethamine/sulfadiazine and pyrimethamine/clindamycin in patients with AIDS and toxoplasmic encephalitis.

Authors:  E Caumes; H Bocquet; G Guermonprez; O Rogeaux; F Bricaire; C Katlama; M Gentilini
Journal:  Clin Infect Dis       Date:  1995-09       Impact factor: 9.079

9.  Assessment of therapy for toxoplasma encephalitis. The TE Study Group.

Authors:  H W Haverkos
Journal:  Am J Med       Date:  1987-05       Impact factor: 4.965

10.  Isolation, identification and determination of sulfadiazine and its hydroxy metabolites and conjugates from man and rhesus monkey by high-performance liquid chromatography.

Authors:  T B Vree; E Schoondermark-van de Ven; C P Verwey-van Wissen; A M Bars; A Swolfs; P M van Galen; H Amatdjais-Groenen
Journal:  J Chromatogr B Biomed Appl       Date:  1995-08-04
View more
  4 in total

1.  Treatment of infants with congenital toxoplasmosis: tolerability and plasma concentrations of sulfadiazine and pyrimethamine.

Authors:  Dorte Remmer Schmidt; Birthe Hogh; Ole Andersen; Steen Honoré Hansen; Kim Dalhoff; Eskild Petersen
Journal:  Eur J Pediatr       Date:  2005-08-20       Impact factor: 3.183

Review 2.  A Systematic Review and Meta-Analysis of the Efficacy of Anti-Toxoplasma gondii Medicines in Humans.

Authors:  Hai-Xia Wei; Shan-Shan Wei; David S Lindsay; Hong-Juan Peng
Journal:  PLoS One       Date:  2015-09-22       Impact factor: 3.240

Review 3.  Systemic and Target-Site Pharmacokinetics of Antiparasitic Agents.

Authors:  Valentin Al Jalali; Markus Zeitlinger
Journal:  Clin Pharmacokinet       Date:  2020-07       Impact factor: 6.447

Review 4.  HIV-Related Cerebral Toxoplasmosis Revisited: Current Concepts and Controversies of an Old Disease.

Authors:  José Ernesto Vidal
Journal:  J Int Assoc Provid AIDS Care       Date:  2019 Jan-Dec
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.